These results support our hypothesis that Mps1-targeted therapy will be better tolerated when combined with CDK4/6 inhibition in Rb1-dysregulated cancers (e.g. HPV-induced cervical cancer, HPV+ head and neck squamous cell carcinomas). Here, CDK4 is linked to cancer.